Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.810
+0.030 (1.69%)
At close: Apr 23, 2025, 4:00 PM
1.820
+0.010 (0.55%)
After-hours: Apr 23, 2025, 7:40 PM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Taysha Gene Therapies stock have an average target of 6.63, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 266.30% from the current stock price of 1.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +231.49% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +231.49% | Feb 27, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +286.74% | Feb 26, 2025 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +231.49% | Jan 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +341.99% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
6.85M
from 8.33M
Decreased by -17.86%
Revenue Next Year
3.81M
from 6.85M
Decreased by -44.31%
EPS This Year
-0.38
from -0.36
EPS Next Year
-0.45
from -0.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 11.4M | 85.1M | ||
| Avg | 6.8M | 3.8M | 43.8M | ||
| Low | n/a | n/a | 7.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.0% | 67.2% | 2,131.4% | ||
| Avg | -17.9% | -44.3% | 1,048.5% | ||
| Low | - | - | 107.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.33 | -0.34 | 1.42 | ||
| Avg | -0.38 | -0.45 | -0.00 | ||
| Low | -0.42 | -0.73 | -0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.